Perspective Therapeutics Inc (CATX) Stock Price, Quote & News

Company Profile

Perspective Therapeutics, Inc., together with its subsidiaries, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. The company discovers, and develop its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a bet...

Industry: Medical Devices

Sector: Healthcare

Phone: 206 676 0900

Website: www.perspectivetherapeutics.com

Address:

2401 Elliott Avenue, Suite 320, Seattle, United States

drdenturedds Aug. 3 at 10:38 PM

$CATX New article on Seeking Alpha regarding Perspective Therapeutics.

0 · Reply

Jcljack26 Aug. 1 at 8:41 PM

$CATX unfortunately the downward trend continues, need some news to break it. Solid support at 3.50

0 · Reply

Alacrity2 Aug. 1 at 5:23 PM

$CATX jto2 posted this link to the new and improved website … but just in case you missed it. https://www.linkedin.com/posts/perspective-therapeutics_a-radiotherapeutic-is-more-than-just-a-radioactive-activity-7356697753978032128-wgYl?utm_medium=ios_app&rcm=ACoAACVaBNsBrvfIvbW16ta28vS1MkGGk6XkjWE&utm_source=social_share_send&utm_campaign=copy_link

0 · Reply

Nowayroy Aug. 1 at 1:36 PM

$CATX At 3.65 I will put in my order for 5k at 3.50

0 · Reply

jto2 Aug. 1 at 1:11 PM

Schwab’s analyst report on $CATX is out — likely their first. Coverage like this is rare for a micro-cap. With LSEG coverage and stealthy accumulation, it’s starting to pop up on more radars. Time might be ticking. And keep in mind, $CATX benefits from pharma tariffs but isn’t impacted by Trump’s drug price cuts like big pharma — it’s a new drug.

0 · Reply

jto2 Aug. 1 at 10:15 AM

$CATX Vanguard Russell 2000 Index Fund reports increase in ownership of CATX / Perspective Therapeutics, Inc. On July 29, 2025

0 · Reply

Alacrity2 Aug. 1 at 2:29 AM

$CATX sweet ! https://www.linkedin.com/posts/perspective-therapeutics_nuclearmedicine-biotech-radiopharmaceuticals-activity-7355655768391516160-aD3m?utm_medium=ios_app&rcm=ACoAACVaBNsBrvfIvbW16ta28vS1MkGGk6XkjWE&utm_source=social_share_send&utm_campaign=copy_link

0 · Reply

Jcljack26 Jul. 31 at 8:39 PM

$CATX Gotta snap the down trend with some news

0 · Reply

jto2 Jul. 31 at 2:40 PM

$CATX Shorts have been suppressing the price for days on low volume, but now it looks like short covering is starting in earnest. If you're considering adding shares or averaging down, this could be a good spot to do it

2 · Reply

jto2 Jul. 31 at 2:17 PM

$CATX could be a good fit for both Trump’s CNPV program and FNIH’s AMP, plus it already has Fast Track status for faster approval. https://fnih.org/our-programs/accelerating-medicines-partnership-amp/

0 · Reply

Perspective Therapeutics: Giving Us Some Valuable Perspective On Alpha Emitter Therapy

Jul 24, 2025, 12:45 PM EDT - 10 days ago

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025

Jul 15, 2025, 7:00 AM EDT - 19 days ago

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results

Jun 21, 2025, 8:00 AM EDT - 6 weeks ago

Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial

Jun 21, 2025, 8:00 AM EDT - 6 weeks ago

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting

May 30, 2025, 5:21 PM EDT - 2 months ago

Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

May 12, 2025, 4:36 PM EDT - 2 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results

May 1, 2025, 7:00 AM EDT - 3 months ago

Perspective Therapeutics to Participate in Upcoming May Investor Conferences

Apr 23, 2025, 12:25 PM EDT - 3 months ago

Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting

Apr 17, 2025, 7:00 AM EDT - 3 months ago

Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results

Apr 11, 2025, 7:00 AM EDT - 4 months ago

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Mar 31, 2025, 7:00 AM EDT - 4 months ago

Perspective Therapeutics to Participate in Upcoming April Investor Conferences

Mar 26, 2025, 4:10 PM EDT - 4 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results

Mar 17, 2025, 7:00 AM EDT - 4 months ago

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Mar 13, 2025, 2:52 PM EDT - 5 months ago

Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst

Feb 26, 2025, 7:00 AM EST - 5 months ago

Perspective Therapeutics to Present at Upcoming March Investor Conferences

Feb 21, 2025, 7:00 AM EST - 5 months ago

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results

Feb 5, 2025, 7:00 AM EST - 6 months ago

Perspective Therapeutics to Participate in Upcoming February Investor Conferences

Jan 24, 2025, 7:00 AM EST - 6 months ago

Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

Jan 6, 2025, 8:00 AM EST - 7 months ago

Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer

Dec 23, 2024, 11:13 AM EST - 7 months ago

Bullish On Perspective Therapeutics: Early Successes And Large Oncology TAM

Dec 20, 2024, 4:16 PM EST - 8 months ago

Perspective Therapeutics: Definitely Not Looking Overvalued Now

Nov 27, 2024, 7:00 AM EST - 8 months ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in December

Nov 21, 2024, 7:15 AM EST - 9 months ago

Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium

Nov 15, 2024, 4:08 PM EST - 9 months ago

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

Nov 12, 2024, 4:05 PM EST - 9 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

Oct 29, 2024, 7:00 AM EDT - 9 months ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in November

Oct 23, 2024, 7:00 AM EDT - 10 months ago

Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine

Oct 16, 2024, 7:00 AM EDT - 10 months ago

Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey

Oct 11, 2024, 12:05 PM EDT - 10 months ago

Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report

Oct 11, 2024, 8:30 AM EDT - 10 months ago

Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research

Oct 10, 2024, 5:14 PM EDT - 10 months ago

Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research

Oct 7, 2024, 7:00 AM EDT - 10 months ago

Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day

Oct 2, 2024, 3:11 PM EDT - 10 months ago

Perspective: VMT01/02 Melanoma Data Coming For Radiotherapeutic Proof-Of-Concept

Oct 2, 2024, 12:10 PM EDT - 10 months ago

Perspective Therapeutics Inc (CATX) Trading 3.4% Higher on Oct 2

Sep 30, 2024, 7:00 AM EDT - 10 months ago

Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine

Sep 5, 2024, 7:00 AM EDT - 11 months ago

Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma

Aug 28, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in September

Aug 12, 2024, 4:05 PM EDT - 1 year ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results

Jul 30, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate at Upcoming Investor Conferences in August

Jul 22, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2024 Financial Results

Jun 12, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Announces Inclusion in the Russell 3000® Index

Jun 11, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Announces 1-for-10 Reverse Stock Split

Jun 10, 2024, 4:10 PM EDT - 1 year ago

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting

May 24, 2024, 8:01 AM EDT - 1 year ago

Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

May 20, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024

May 15, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results

May 3, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate at Upcoming May Investor Conferences

May 2, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results

Apr 30, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs

drdenturedds Aug. 3 at 10:38 PM

$CATX New article on Seeking Alpha regarding Perspective Therapeutics.

0 · Reply

Jcljack26 Aug. 1 at 8:41 PM

$CATX unfortunately the downward trend continues, need some news to break it. Solid support at 3.50

0 · Reply

Alacrity2 Aug. 1 at 5:23 PM

0 · Reply

Nowayroy Aug. 1 at 1:36 PM

$CATX At 3.65 I will put in my order for 5k at 3.50

0 · Reply

jto2 Aug. 1 at 1:11 PM

0 · Reply

jto2 Aug. 1 at 10:15 AM

$CATX Vanguard Russell 2000 Index Fund reports increase in ownership of CATX / Perspective Therapeutics, Inc. On July 29, 2025

0 · Reply

Alacrity2 Aug. 1 at 2:29 AM

0 · Reply

Jcljack26 Jul. 31 at 8:39 PM

$CATX Gotta snap the down trend with some news

0 · Reply

jto2 Jul. 31 at 2:40 PM

2 · Reply

jto2 Jul. 31 at 2:17 PM

0 · Reply

morty104 Jul. 30 at 7:06 PM

$CATX welcome new baggies. Confused? It’s ok, we all are. Sit back for the ride

3 · Reply

jto2 Jul. 30 at 6:28 PM

$CATX Anyone checked out the updated CATX website? You can totally tell they spent some cash on it. Check news section too. https://perspectivetherapeutics.com/

0 · Reply

David_M_ Jul. 30 at 5:09 PM

$CATX

0 · Reply

bhunts4 Jul. 30 at 3:56 PM

$CATX live well and prosper. Keep adding $6 let's go!!! GLTA keep

0 · Reply

morty104 Jul. 30 at 1:09 PM

$CATX 3.999998 time.

1 · Reply

jto2 Jul. 30 at 12:43 PM

Fidelity increased $CATX 51% as per 13F. Q2

2 · Reply

jto2 Jul. 30 at 12:12 AM

This article explains $CATX well, but the clinical data is only updated through Q1. It’s still worth a read, and you might want to consider increasing your position.

0 · Reply

NVDAMillionaire Jul. 29 at 9:09 PM

$CATX Outstanding article that hits the mark on CATX's current state. So if you want to refresh your CATX insights or learn about CATX from scratch, this is a must read. https://beyondspx.com/article/perspective-therapeutics-alpha-emitter-pipeline-advances-amidst-strategic-transformation-nyseamerican-catx

0 · Reply

chromeal5 Jul. 29 at 7:03 PM

$CATX I don't think this administration cares about cancer. For everyone who dies, that is just one less "entitled" American, who is perceived as a mooch when they collect what they have paid in their whole lives.

0 · Reply

morty104 Jul. 29 at 3:48 PM

$CATX noble is a trader/short dude. Look at his other posts. He’s the problem here.

3 · Reply

srod1122 Jul. 29 at 1:57 PM

$CATX and so why the drop

1 · Reply

noble23 Jul. 29 at 1:11 PM

$HIMS $CATX the new. Drug dealer in town

0 · Reply

Market Cap	273.16M
Revenue (ttm)	1.45M
Net Income (ttm)	-79.28M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-5,467.59%
Debt to Equity Ratio	0.01

Volume	686,900
Avg Vol	1,277,134
Day's Range	N/A - N/A
Shares Out	74.23M
Stochastic %K	4%
Beta	1.16
Analysts	Strong Sell
Price Target	$12.64